|
시장보고서
상품코드
2024675
고콜레스테롤혈증 시장 규모 : 유형별, 진단·치료별, 환자별, 최종사용자별, 지역별(2026-2034년)Hypercholesterolemia Market Size by Type, Diagnosis and Treatment, Patient, End User, and Region 2026-2034 |
||||||
세계의 고콜레스테롤혈증 시장 규모는 2025년에 227억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 650억 달러에 달하며, 2026-2034년에 CAGR 12.03%로 성장할 것으로 예측하고 있습니다. 건강 인식의 증가, 고령 인구의 증가, 활발한 연구개발(R&D) 활동은 시장 성장을 이끄는 주요 요인 중 일부입니다.
고콜레스테롤혈증은 혈액내 저밀도 지단백(LDL)이 과다하게 축적되는 이상지질혈증으로 알려져 있습니다. 고콜레스테롤혈증을 유발하는 흔한 질환으로는 당뇨병, 다낭성난소증후군, 갑상선기능저하증, 신장질환 등이 있습니다. 이 질환은 장기적인 질환으로 흉통, 숨가쁨, 극심한 피로, 근력 약화 등이 가장 흔한 증상입니다. 고콜레스테롤혈증은 생명을 위협하는 심각한 질환으로, 혈액내 나쁜 콜레스테롤 수치를 낮추는 동시에 간에서 유해한 콜레스테롤 생성을 억제하기 위해 약물이 사용됩니다. 이러한 약물은 혈관벽의 플라크를 안정화시키고 특정 혈전 위험을 줄이는 데 도움이 됩니다. 또한 심장마비, 뇌졸중, 혈관 기능 장애의 위험도 감소시킵니다.
고콜레스테롤혈증 시장 동향:
일반인들의 건강에 해로운 생활습관 증가에 따른 고콜레스테롤혈증 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 이에 따라 심혈관 질환(CVD), 당뇨병, 신장 합병증, 갑상선 질환 등 다양한 만성질환에 취약한 고령 인구의 증가가 시장 성장을 촉진하고 있습니다. 또한 건강에 대한 인식이 높아지고 고콜레스테롤혈증에 대한 치료법에 대한 인식이 높아진 것도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이와 더불어, 고콜레스테롤혈증 환자의 지질 프로파일을 정상에 가깝게 유지하고 심혈관 질환의 발병 위험을 줄이기 위한 다양한 약물 및 치료법의 도입이 시장 성장에 큰 탄력을 받고 있습니다. 이와 더불어 효능과 안전성이 개선된 새로운 약제군의 개발이 시장 성장에 탄력을 받고 있습니다. 또한 고콜레스테롤혈증 치료를 목적으로 다른 콜레스테롤 저하제와의 다양한 병용요법의 도입도 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한 내피 기능 개선, 산화 스트레스로 인한 세포 손상 감소, 동맥경화 플라크 안정화, 염증 억제 등 다양한 장점으로 인해 스타틴의 보급이 확대되고 있는 것도 시장 성장을 촉진하고 있습니다. 이 외에도 헬스케어 인프라의 전반적인 개선, 신약 개발을 위한 광범위한 연구개발(R&D) 활동, 가족성 고콜레스테롤혈증 환자 수 증가 등의 요인이 시장 성장을 촉진할 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문:
- 세계 고콜레스테롤혈증 시장은 지금까지 어떤 추세를 보였으며, 향후 수년간 어떤 추세를 보이는가?
- 세계의 고콜레스테롤혈증 시장 촉진요인, 억제요인 및 기회는 무엇인가?
- 주요 지역 시장은 어디인가?
- 가장 유리한 고콜레스테롤혈증 시장을 대표하는 국가는 어디인가?
- 시장 유형별 시장 분석은?
- 진단 및 치료별 시장 현황은?
- 환자별 시장 현황은?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 세계의 고콜레스테롤혈증 시장의 경쟁 구조는 어떠한가?
- 세계의 고콜레스테롤혈증 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 고콜레스테롤혈증 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 진단·치료별
제8장 시장 내역 : 환자별
제9장 시장 내역 : 최종사용자별
제10장 시장 내역 : 지역별
제11장 촉진요인·억제요인·기회
제12장 밸류체인 분석
제13장 Porters Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSA 26.05.18The global hypercholesterolemia market size reached USD 22.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 65.0 Billion by 2034, exhibiting a growth rate (CAGR) of 12.03% during 2026-2034. Rising health consciousness, increasing geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market growth.
Hypercholesterolemia is a lipid disorder known for an excess of low-density lipoprotein (LDL) in the blood. Some of the common conditions that lead to hypercholesterolemia are diabetes, polycystic ovary syndrome, underactive thyroid gland, and kidney diseases. It is a long-term condition, and chest pain, shortness of breath, extreme fatigue, and muscle weakness are some of the most common symptoms. Hypercholesterolemia is a serious life-threatening ailment wherein drugs are used to decrease the level of bad cholesterol in the blood while reducing the liver's production of harmful cholesterol. These drugs help stabilize the plaques on blood vessel walls and reduce the risk of certain blood clots. They also reduce the risk of a heart attack or stroke and dysfunction in the blood vessels.
Hypercholesterolemia Market Trends:
The growing prevalence of hypercholesterolemia due to the rising unhealthy lifestyle among the masses is one of the key factors driving the market growth. In line with this, the increasing geriatric population that is susceptible to cardiovascular disorders (CVDs) and various other chronic diseases, such as diabetes, kidney complications, and thyroid problems, is favoring the market growth. Moreover, the rising health consciousness and the increasing awareness regarding the available treatment alternatives for hypercholesterolemia are acting as other growth-inducing factors. Along with this, the introduction of various drugs and therapies to achieve near-normal lipid profiles in hypercholesterolemia patients and reduce the risk of CVDs occurrence in patients is providing a considerable boost to the market growth. Apart from this, the development of novel drug classes with enhanced efficacy and safety profile is providing an impetus to the market growth. Additionally, the launch of various combination therapies with other cholesterol-diminishing compounds to treat hypercholesterolemia is positively influencing the market growth. Besides this, the widespread adoption of statins due to their several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation is facilitating the market growth. Other factors, including overall improvements in the healthcare infrastructure, extensive research, and development (R&D) activities for developing novel drugs, and the increasing number of familial hypercholesterolemia patients, are anticipated to drive the market growth.
Key Market Segmentation:
This report provides an analysis of the key trends in each segment of the global hypercholesterolemia market, along with forecasts at the global, regional, and country level from 2026-2034. The report has categorized the market based on type, diagnosis and treatment, patient, and end user.
Type Insights:
- Type 1
- Type 2A
- Type 2B
- Type 3
- Type 4
- Type 5
- Others
Diagnosis and Treatment Insights:
- Diagnosis
- Cholesterol Test
- Genetic Testing
- Treatment
- Statins
- Niacin
- Bile Acid Resins
- Fibric Acid Derivatives
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
- Others
Patient Insights:
- Pediatric
- Adults
- Geriatric
End User Insights:
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hypercholesterolemia. Some of the factors driving the North America hypercholesterolemia market included its growing prevalence of hypercholesterolemia, increasing geriatric population, and rising unhealthy lifestyle among the masses.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global hypercholesterolemia market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., Dr. Reddy's Laboratories, Lupin Limited, Novartis AG, Regeneron Pharmaceuticals, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global hypercholesterolemia market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global hypercholesterolemia market?
- What are the key regional markets?
- Which countries represent the most attractive hypercholesterolemia markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the diagnosis and treatment?
- What is the breakup of the market based on patient?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global hypercholesterolemia market?
- Who are the key players/companies in the global hypercholesterolemia market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hypercholesterolemia Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Type 1
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Type 2A
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Type 2B
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Type 3
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Type 4
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Type 5
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Diagnosis & Treatment
- 7.1 Diagnosis
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Cholesterol Test
- 7.1.2.2 Genetic Testing
- 7.1.3 Market Forecast
- 7.2 Treatment
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Statins
- 7.2.2.2 Niacin
- 7.2.2.3 Bile Acid Resins
- 7.2.2.4 Fibric Acid Derivatives
- 7.2.2.5 Cholesterol Absorption Inhibitors
- 7.2.2.6 PCSK9 Inhibitors
- 7.2.2.7 Others
- 7.2.3 Market Forecast
8 Market Breakup by Patient
- 8.1 Pediatric
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Adults
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Geriatric
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Specialty Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Home Healthcare
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Amgen Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Dr. Reddy's Laboratories
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Lupin Limited
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Novartis AG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Regeneron Pharmaceuticals, Inc
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.1 Amgen Inc.
